Core Viewpoint - The mosquito-repellent concept stocks continue to show strong performance, driven by the reported cases of Chikungunya fever in Foshan, with a total of 3,195 confirmed cases as of July 22, primarily concentrated in Shunde District [1] Group 1: Company Performance - Rainbow Group has achieved a consecutive two-day increase in stock price [1] - Kangzhi Pharmaceutical has seen a rise of over 10% in its stock price [1] - Other companies such as Runben Co., Wanfang Biological, Shanghai Jahwa, Qingsong Co., and Lafang Co. have also experienced stock price increases [1]

Core Insights - The in vitro diagnostics (IVD) industry is a crucial component of modern healthcare, providing essential data for disease prevention, diagnosis, and treatment through various testing methods [1][5][10] - China's IVD market has surpassed 120 billion yuan in 2024, with a projected growth to 165 billion yuan by 2029, reflecting a compound annual growth rate of 5-8% [1][10][19] - The industry is experiencing significant domestic substitution, with over 80% of Class III diagnostic products being domestically produced, while the share of imported products has decreased from 29.3% to 19.5% from 2021 to 2024 [1][14] Industry Overview - IVD encompasses several testing methods, including biochemical, immunological, molecular, microbiological, blood diagnostics, and point-of-care testing (POCT) [2][5] - The industry is transitioning from scale expansion to high-quality development, driven by government policies and technological innovations [5][21] Policy and Regulatory Environment - Recent government policies, such as the "14th Five-Year Plan for Bioeconomic Development" and the "Comprehensive Action Plan for Improving Medical Quality (2023-2025)," provide a strong impetus for the IVD industry [5][7] - The introduction of the "List of In Vitro Diagnostic Reagents Exempt from Clinical Trials (2025)" has expanded the range of products available in the market [7] Market Dynamics - The IVD industry is characterized by a multi-tiered market structure, with foreign giants dominating the high-end market and domestic leaders gradually increasing their market share [15][19] - The competitive landscape is evolving, with leading companies like Mindray Medical and New Industry Bio showing strong performance, while former leaders in COVID-19 testing, such as Da An Gene and BGI, are seeking business transformation [19][20] Growth Trends - The IVD industry is witnessing a shift towards precision and intelligent diagnostics, with advancements in molecular diagnostics, chemiluminescence, and POCT technologies [21][22] - The integration of AI and big data is enhancing diagnostic efficiency, while the demand for home health management and early cancer screening is rising due to an aging population [21][24] Competitive Landscape - The first tier of the market is dominated by international giants like Roche and Abbott, while domestic leaders such as Mindray and New Industry Bio are gaining traction in immunological and molecular diagnostics [15][19] - The market is seeing increased consolidation, with leading companies acquiring smaller firms to enhance their technological capabilities [23] Registration and Product Development - The registration of IVD products has been robust, with a compound annual growth rate of 25.3% from 2021 to 2024, indicating a vibrant development in the sector [14] - In 2024, the registration of domestic Class III diagnostic products reached 533, accounting for 80.5% of total IVD product registrations [14]

Group 1: Company Announcements - Chenfeng Technology plans to invest 90 million yuan in its wholly-owned subsidiary, Beiwang Zhican, to support its business development and create a new ecosystem for integrated power computing [1] - Daotong Technology's controlling shareholder proposes a mid-term dividend of 5.8 yuan per 10 shares for the year 2025 [4] - Huazheng New Materials' supervisors and executives plan to reduce their holdings by a total of no more than 124,900 shares [5] - Kuozi Jiao's controlling shareholder intends to reduce its stake by no more than 1.67% [9] - Rundu Co., Ltd.'s controlling shareholder plans to reduce its stake by no more than 3% [14] Group 2: Performance Forecasts - China First Heavy Industries expects a net loss of 90 million to 108 million yuan for the first half of 2025, an improvement from a net loss of 173 million yuan in the same period last year [2] Group 3: Shareholder Actions - China Xidian's shareholder, General Electric Singapore, plans to reduce its stake by no more than 3% [3] - Boguang New Materials' shareholder, Newhui Investment, plans to reduce its stake by no more than 1% [8] - Donghong Co., Ltd. has won a procurement project for pressure steel pipes and accessories worth 109 million yuan [6] - Tianshi Technology's wholly-owned subsidiary has resumed production after a temporary shutdown due to supplier issues [12] - Baichuan Co., Ltd.'s controlling shareholder has returned to work and is performing normal duties after being detained [13]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"万孚生物"或"公司"）近日 收到国家药品监督管理局颁发的医疗器械注册证，具体信息如下： | 名称 | 注册证号 | 有效期至 | 预期用途 | | --- | --- | --- | --- | | | | 2030/07/16 | 本试剂盒用于体外定性检测结直肠癌患者福尔马 | | | | | 林固定石蜡包埋（Formalin fixed paraffin | | 人类微卫星不稳定性 | | | embedding，FFPE）肿瘤组织样本中微卫星位点 | | （MSI）检测试剂盒 | 国械注准 | | ACVR2A、CENPQ、SLC22A9、LRIG2、 | | （荧光 PCR 熔解曲 | 20253401409 | | DIDO1、MRE11、TGFBR2、PSIP1，根据微卫 | | 线法） | | | 星位点不稳定的数量，将结直肠癌分为微卫星高 | | | | | 度术稳定型（MSI-H）和微卫星高度不稳定型 | | | | | （non-MSI-H，即 MSS ...

Group 1 - Multiple medical devices and diagnostic kits have passed the quality management system inspection and are set to be approved for market use by June 2025 [3][4][5][6][7][8] - Companies involved include Shenzhen Sogang Technology Co., Ltd., Shenzhen Puhui Medical Technology Co., Ltd., and Guangzhou Wanfu Biotechnology Co., Ltd., among others [3][4][5][6][7][8] - The products range from laser treatment devices to diagnostic kits for various medical conditions, indicating a diverse portfolio in the medical technology sector [3][4][5][6][7][8] Group 2 - The inspections are part of a regulatory framework established by the Guangdong Provincial Drug Administration to ensure the quality and safety of medical devices [8] - The approval process includes a thorough review of manufacturing practices and compliance with established standards [8] - The timeline for passing inspections and receiving approvals is critical for companies aiming to launch their products in the competitive medical device market [8]

广州万孚生物技术股份有限公司董事会 公司债权人如要求公司清偿债务或提供相应担保的，应根据《中华人民共和国公司法》等相关法律法规 的规定，向公司提出书面要求，并附随有关证明文件。如债权人未在规定期限内行使上述权利的，公司 本次回购注销限制性股票将按法定程序继续实施。 特此公告。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 2025年7月4日，广州万孚生物技术股份有限公司（以下简称"公司"）召开2025年第一次临时股东大会， 审议通过了《关于终止实施 2024 年限制性股票激励计划暨回购注销限制性股票的议案》，因公司经营 所面临的内外部环境与制定股权激励计划时相比发生了较大变化，导致公司预期经营情况与激励方案考 核指标的设定存在偏差，继续推进和实施激励计划难以达到对激励对象的激励效果。经公司董事会审慎 考虑后，决定终止实施 2024 年限制性股票激励计划，并回购注销公司 2024 年限制性股票激励计划所涉 及的已授予但尚未解除限售的限制性股票 1054.40 万股，同时与之配套的《2024 年限制性股票激励计划 实施考核管理办法》等相关文件一并终止。具体内容详见公司 ...

广州万孚生物技术股份有限公司 关于回购注销部分限制性股票减少注册资本 暨通知债权人的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 2025 年 7 月 4 日，广州万孚生物技术股份有限公司（以下简称"公司"）召 开 2025 年第一次临时股东大会，审议通过了《关于终止实施 2024 年限制性股 票激励计划暨回购注销限制性股票的议案》，因公司经营所面临的内外部环境与 制定股权激励计划时相比发生了较大变化，导致公司预期经营情况与激励方案考 核指标的设定存在偏差，继续推进和实施激励计划难以达到对激励对象的激励效 果。经公司董事会审慎考虑后，决定终止实施 2024 年限制性股票激励计划，并 回购注销公司 2024 年限制性股票激励计划所涉及的已授予但尚未解除限售的 限制性股票 1054.40 万股，同时与之配套的《2024 年限制性股票激励计划实施 考核管理办法》等相关文件一并终止。具体内容详见公司于 2025 年 6 月 18 日披 露在巨潮咨询网（http://www.cninfo.com.cn）上的《关于终止实施 2024 年限制性 股票激励计划暨回购注销限 ...

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2025-034 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 2025 年第一次临时股东大会会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会于 2025 年 7 月 4 日 14:00 在公司 D 座三楼会议室召开。会议通知已于 2025 年 6 月 18 日在中国证监会指定的信息披露网站公告。本次股东大会由公 司董事会召集，董事长王继华女士主持，公司全体董事、监事、高级管理人 员、公司聘请的见证律师等相关人士出席、列席了本次会议。会议的召集、召 开与表决程序符合《公司法》和《公司章程》的规定。 股东出席情况：通过现场和网络投票的股东 301 人，代表股份 210,616,079 股，占公司有表决权股份总数的 43.7485％。其中： 特别提示： 1、本次股东大会无增加、变更、提案的情况。 2、本次股东大会以现场投票和网络投票相结合的 ...

北京市君合（广州）律师事务所 关于 广州万孚生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 二零二五年七月 | 北京总部 | 电话: (86-10) 8519-1300 | 上海分所 | 电话: (86-21) 5298-5488 | 广州分所 | 电话: (86-20) 2805-9088 | 深圳分所 | 电话: (86-755) 2939-5288 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 传真: (86-10) 8519-1350 | | 传真: (86-21) 5298-5492 | | 传真: (86-20) 2805-9099 | | 传真: (86-755) 2939-5289 | | 杭州分所 | 电话: (86-571) 2689-8188 | 成都分所 | 电话: (86-28) 6739-8000 | 西安分所 | 电话: (86-29) 8550-9666 | 青岛分所 | 电话: (86-532) 6869-5000 | | | 传真: (86-571) 2689-8199 | | 传真: ( ...

Core Viewpoint - The China Securities Social Development Security Industry Theme Index (CSI Security) has shown mixed performance, with a recent increase of 0.58% and a year-to-date rise of 0.39% [1]. Group 1: Index Performance - The CSI Security Index rose by 2.28% over the past month, but has decreased by 3.03% over the last three months [1]. - The index was established on June 29, 2012, with a base value of 1000.0 points [1]. Group 2: Index Composition - The top ten weighted stocks in the CSI Security Index include: - Huace Testing (9.28%) - Hikvision (7.9%) - Zhongke Shuguang (3.59%) - Wanfu Biology (2.94%) - Greenme (2.88%) - Meiya Optoelectronics (2.77%) - Southern Network Technology (2.48%) - Siwei Liekong (2.48%) - Dahua Technology (2.43%) - Aerospace Zhizhuang (2.4%) [1]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (67.13%) and the Shanghai Stock Exchange (32.87%) [1]. Group 3: Industry Breakdown - The industry composition of the index includes: - Industrial sector: 42.43% - Information technology: 41.81% - Public utilities: 5.46% - Communication services: 4.97% - Healthcare: 4.88% - Financial sector: 0.45% [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]. Group 5: Related Funds - Public funds tracking the CSI Security Index include Donghai CSI Social Development Security [3].